Phaseline

Targets › VEGFR3

VEGFR3 (Vascular endothelial growth factor receptor 3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. (UniProt, P35916)

Open in Phaseline: the race on VEGFR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fei GaoDonafenib
Multi-kinase inhibitor targeting FGFR and VEGFR
FGFR1, VEGFR1, VEGFR2, VEGFR3Phase 2Hepatocellular Carcinoma with PVTTDec 2026
Karie RuncieZanzalintinib (XL092)
Multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors
VEGFR1, VEGFR2, VEGFR3Phase 2Advanced Renal Cell CarcinomaDec 2027

Conditions

Advanced Renal Cell Carcinoma (1) Hepatocellular Carcinoma with PVTT (1)

Modalities

mixed (1), small molecule (1)

Companies

Karie Runcie (1) Fei Gao (1)

Related targets

VEGFR1 (2) VEGFR2 (2) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.